Chronic heart failure (CHF) and NEW drugs: analytical review of efficacy
Abstract
Chronic heart failure (CHF) is a multifactorial clinical syndrome characterized by impaired cardiac pumping function, reduced exercise tolerance, and frequent hospitalizations, posing a significant global health burden. Traditional pharmacotherapy, including ACE inhibitors, beta-blockers, and diuretics, improves symptoms and survival but often fails to fully address disease progression or quality of life. Recent advances in pharmacology have introduced novel therapeutic agents targeting key pathophysiological mechanisms in CHF, including angiotensin–neprilysin inhibitors (ARNIs), sodium–glucose cotransporter-2 (SGLT2) inhibitors, myotropic agents, and anti-inflammatory drugs. These therapies aim to enhance cardiac function, optimize neurohormonal balance, improve myocardial energetics, and reduce systemic inflammation. Sacubitril/valsartan, an ARNI, combines angiotensin receptor blockade with neprilysin inhibition, enhancing natriuretic peptide activity and promoting vasodilation. Clinical trials demonstrate reduced mortality and hospitalization rates, improved symptom management, and long-term survival benefits in patients with reduced ejection fraction. SGLT2 inhibitors, originally developed for diabetes management, including empagliflozin, have shown cardioprotective effects by reducing renal sodium and glucose reabsorption, promoting diuresis, and enhancing ventricular performance, independent of glycemic control. Omecamtiv mecarbil, a myotropic agent, improves…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.